Clinical Trial Applications - Approved: Filter, Search, and view applications


Clear
Extended search...

Page 23 of 24, showing 10 Applications out of 238 total, starting on record 221, ending on 230

# Protocol No Study Title Investigator(s) & Site(s) Date Approved

221.

ECCT/21/03/02   PB-SAM
    Pancreatic Enzymes and Bile Acids: A Non-Antibiotic approach to Treat Intestinal Dysbiosis in Acutely Ill Severely Malnourished Children.   
Principal Investigator(s)
1. Robert Bandsma
Site(s) in Kenya
1. Kilifi County Hospital (Kilifi county)
2. Coast General Hospital (Mombasa county)
3. Mbagathi Hospital (Nairobi City county)
4. Migori County Hospital (Migori county)
 
08-06-2021 View

222.

ECCT/08/20/01   Partners PrEP Study
    Parallel comparison of Tenofovir and Emtricitabine/Tenofovir pre exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples   
Principal Investigator(s)
1. James Njogu Kiarie
2. CAREY FARQUHAR,
3. Grace John Stewart
Site(s) in Kenya
1. Nairobi (Nairobi City county)
2. Thika (Kiambu county)
3. Eldoret (Uasin Gishu county)
4. Kisumu (Kisumu county)
 
09-10-2013 View

223.

ECCT/08/08/03   Partners PrEP Study
    Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition  within HIV-1 Discordant Couples.    
Principal Investigator(s)
1. Prof. Connie Celum
Site(s) in Kenya
1. Kenya- Eldoret (Uasin Gishu county)
2. Kenya – Nairobi (Nairobi City county)
3. Kenya – Kisumu (Kisumu county)
4. Kenya – Thika (Uasin Gishu county)
 
12-11-2008 View

224.

ECCT/08/06/01   PARTNERS PrEP
    Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. Kisumu site (Kisumu county)
 
30-07-2008 View

225.

ECCT/23/10/03   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)   
Principal Investigator(s)
1. Dr. Lucas Tina, Otieno
2. Prof. Kariuki Simon
3. Dr. Janet Nyawira Oyieko
4. Walter Otieno
5. Onono Dr. Marciana
6. Prof. Walter Jaoko
7. Dr Fredrick Sawe
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
4. Siaya County Referral Hospital (SCRH (Siaya county)
5. Kenya Medical Research Institute Center for Microbiology Research (CMR (Kisumu county)
6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
7. Kombewa Clinical Research Center, KEMRI, (Kisumu county)
 
12-03-2024 View

226.

ECCT/23/12/02   PEARL RSVt Vaccine Study
    Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL)   
Principal Investigator(s)
1. Dr. Maricianah Onono
Site(s) in Kenya
1. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
2. Walter Reed Army Institute of Research -Kericho Site (Kericho county)
3. KEMRI CCR – Butere Clinical Research Centre (Kakamega county)
4. Siaya County Referral Hospital (SCRH) (Siaya county)
5. Kenya Medical Research Institute Center for Microbiology Research (CMR) (Kisumu county)
6. KAVI - Institute of Clinical Research (KAVI - ICR) (Nairobi City county)
7. Kombewa Clinical Research Center, KEMRI, (Kisumu county)
 
10-05-2024 View

227.

ECCT/14/09/02   LIVING STUDY-PHASE III B.
    Prospective study of Lopinavir based ART for HIVInfected childreNGlobally (LIVING study)   
Principal Investigator(s)
1. Elizabeth Maleche Obimbo
2. Elizabeth Bukusi
3. Winstone Nyandiko
4. Bienvenu Baruani Ngoy
5. Joseph Kariuki Mbuthia
6. Allan Godfrey Otieno
7. Lucy Koech
8. Neema Mturi
9. Beatrice Mutai
Site(s) in Kenya
1. University of Nairobi/ Kenyatta National Hospital (Nairobi City county)
2. AMPATH, Moi University Teaching and Referral Hospital Eldoret (Uasin Gishu county)
3. MSF Belgium Kibera Clinic (Nairobi City county)
4. Gertrude\'s Children\'s Hospital (Nairobi City county)
5. Mbagathi District Hospital (Nairobi City county)
 
08-12-2014 View

228.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
07-12-2012 View

229.

ECCT/15/06/01  
    Pyronaridine-artesunate and artemether-lumefantrine for the treatment of paediatric uncomplicated falciparum malaria in Western Kenya   
Principal Investigator(s)
1. Patrick Sawa
Site(s) in Kenya
St. Judes Clinic, ICIPE
 
04-09-2015 View

230.

ECCT/12/09/02   Reduction of EArly mortaLITY in adults and children
    Reduction of EArly mortaLITY in HIVinfected adults and children starting antiretroviral therapy (REALITY)   
Principal Investigator(s)
1. Abraham Mosigisi Siika
Site(s) in Kenya
1. Moi University Clinical Research Centre (Uasin Gishu county)
2. KEMRI Wellcome Trust Research Programme (Kilifi county)
 
04-04-2012 View